"There is potential for cost savings with broader availability and uptake of biosimilar treatment options. All health care stakeholders can collaborate to ensure autoimmune biosimilars have an increasing and comprehensive role in treatment of autoimmune diseases."
— Cathy Starner, Pharm.D., principal health outcomes researcher
at Prime Therapeutics, spoke with AIS's RADAR
on Specialty Pharmacy about the PBM's recent study on pharmacy and
medical benefit drug expenditures in the autoimmune class.
No comments:
Post a Comment